August 5, 2022

The U.S. FDA has approved Nubeqa® (darolutamide – Bayer) for use in combination with docetaxel to treat metastatic hormone-sensitive prostate cancer in males.

  • Nubeqa first received FDA approval in 2019 and is also indicated to treat non-metastatic castration-resistant prostate cancer.
  • Recommended dosing is 600mg (two 300mg tablets) taken by mouth twice daily with food.
August 18, 2022

U.S. FDA Approves First Cetrotide Generic

Read More
August 17, 2022

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

Read More